With weeks to go to COVID-19 vaccine trial, BioNTech lands $135M deal and advances Pfizer talks

BioNTech is in advanced talks with Pfizer over ex-China development of a coronavirus vaccine that is due to enter the clinic late next month. News of the progress of the vaccine and deal-making inside and outside of China sent shares in BioNTech up more than 50%.